



The Delivery of RNA-Based Therapeutics: New Strategies in Cancer and Gene Therapy

Guest Editors:

Dr. Lamiaa M.A. Ali

IBMM, CNRS, ENSCM, Université
de Montpellier, 34093
Montpellier, France

Dr. Nadir Bettache

IBMM, Univ. Montpellier, CNRS,
ENSCM, 34093 Montpellier,
France

Dr. Magali Gary-Bobo

IBMM, University of Montpellier,
CNRS, ENSCM, 34093 Montpellier,
France

Deadline for manuscript
submissions:

closed (20 May 2024)

Message from the Guest Editors

Dear Colleagues,

Ribonucleic acids (RNAs) are important molecular structures that are involved in many functions in cell machinery, including protein synthesis, RNA editing, gene regulation, and RNA interference. Since the fifties of the last century, discoveries are in progress with great promises in RNA therapeutics. Thus far, several RNA-based therapeutics, including antisense oligonucleotides, RNA interference, RNA aptamers, and messenger RNAs, have been approved by the FDA. Nevertheless, their delivery is limited to their encapsulation in lipid-based nanoparticles, in addition of targeting moieties or direct delivery without any modifications. Therefore, the delivery of RNA therapeutics is one of the most controversial and researched topics in RNA therapy. This Special Issue aims to discuss innovative delivery systems and techniques in RNA-based therapeutics to fight cancer and other diseases. In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Guest Editors

Dr. Lamiaa M.A.Ali, Dr. Magali Gary-Bobo, Dr. Nadir Bettache





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma